Johns Hopkins researchers report that their test of an interventional X-ray guidance device approved by the U.S. Food and Drug Administration in 2013 has the potential to reduce the radiation exposure of patients undergoing intra-arterial therapy (IAT) for liver cancer.
In a report prepared for presentation Dec. 3 at the 100th annual meeting of the Radiological Society of North America in Chicago (abstract #SSM24-02), the researchers described the results of a clinical trial of the imaging system AlluraClarity, made by Philips Healthcare, on 50 patients with liver cancer.
Its use reduced radiation exposure up to 80 percent, compared with exposure from a standard imaging X-ray platform used in IAT, while producing images just as clear as the standard system, says Jean-Francois Geschwind, M.D., a professor in the Russell H. Morgan Department of Radiology and Radiological Science in the Johns Hopkins University School of Medicine and its Kimmel Cancer Center.
Geschwind says if further studies continue to affirm his team's findings, the platform may be especially useful for patients who need repeat therapy; children, who are especially vulnerable to radiation; and physicians who routinely use procedures such as IAT and are exposed to radiation.
During IAT, a physician inserts a thin, flexible tube directly into a blood vessel feeding a tumor, using that pathway to deliver chemotherapy or other drugs. X-ray imaging is used during the procedure to visualize the patient's blood vessels and to guide both the catheter's placement and drug delivery.
Geschwind and his colleagues compared the radiation exposure of 25 patients with liver cancer treated with IAT using the AlluraClarity platform to the exposure of 25 additional patients with liver cancer treated with IAT using Philips' previous X-ray imaging platform, called Allura.
Lowering the radiation power on standard X-ray imaging platforms can reduce the exposure, but without special image processing, the amount of image noise increases and physicians are unable to see small structures needed for good treatment, says Ruediger Schernthaner, M.D., a postdoctoral research fellow in vascular and interventional radiology at The Johns Hopkins Hospital. "You can compare this to an image taken with your cell phone in the evening without a flash," he says.
The AlluraClarity platform uses a series of real-time image processing algorithms to achieve high quality images at a lower radiation power, Schernthaner says.
Other researchers who contributed to the study include MingDe Lin of Philips Healthcare (makers of AlluraClarity) and Julius Chapiro, Rafael Duran, and Boris Gorodetski of The Johns Hopkins Hospital.
The study was funded by the Max Kade Foundation, the National Institutes of Health's National Cancer Institute (R01 CA160771) and Philips Research North America.
Geschwind is a consultant for BTG, Guerbet, Boston Scientific and Bayer Healthcare. He is a paid member of the Philips Radiology Medical Advisory Network. He has received grants from National Institutes of Health, Philips Healthcare (makers of AlluraClarity), the Department of Defense, BTG, Bayer HealthCare, Nordion, Context Vision, the Society of Interventional Radiology, the Radiological Society of North America and Guerbet. He is a founder and CEO of PreScience Labs, LLC.
RSNA Abstract: http://rsna2014.rsna.org/program/details/?emID=14011417
Johns Hopkins Medicine (JHM), headquartered in Baltimore, Maryland, is a $7 billion integrated global health enterprise and one of the leading academic health care systems in the United States. JHM unites physicians and scientists of the Johns Hopkins University School of Medicine with the organizations, health professionals and facilities of The Johns Hopkins Hospital and Health System. JHM's vision, "Together, we will deliver the promise of medicine," is supported by its mission to improve the health of the community and the world by setting the standard of excellence in medical education, research and clinical care. Diverse and inclusive, JHM educates medical students, scientists, health care professionals and the public; conducts biomedical research; and provides patient-centered medicine to prevent, diagnose and treat human illness. JHM operates six academic and community hospitals, four suburban health care and surgery centers, and more than 39 Johns Hopkins Community Physicians sites. The Johns Hopkins Hospital, opened in 1889, has been ranked number one in the nation by U.S. News & World Report for 22 years of the survey's 25 year history, most recently in 2013. For more information about Johns Hopkins Medicine, its research, education and clinical programs, and for the latest health, science and research news, visit http://www.hopkinsmedicine.org
Vanessa Wasta | EurekAlert!
New bioimaging technique is fast and economical
21.08.2017 | Rensselaer Polytechnic Institute
Noninvasive eye scan could detect key signs of Alzheimer's years before patients show symptoms
18.08.2017 | Cedars-Sinai Medical Center
Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.
As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...
Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.
Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...
For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.
While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...
An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.
The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...
A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.
Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...
16.08.2017 | Event News
04.08.2017 | Event News
26.07.2017 | Event News
21.08.2017 | Materials Sciences
21.08.2017 | Health and Medicine
21.08.2017 | Materials Sciences